Seedless 3′ pairing enables miR-17 family miRNAs to seize let-7 target sites
Nucleic Acids Research · 10.08.2026 · 54 (15)
DOI: 10.1093/nar/gkag767 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 14.08.2026. Verfasst von Artur Laski und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, 8093, Switzerland. Hauptthemen laut MEDLINE: MicroRNAs, 3' Untranslated Regions. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Krebsliga Schweiz, Foundation Nelia and Amadeo Barletta.
Abstract (Originalsprache)
MicroRNAs (miRNAs) are short noncoding RNAs that post–transcriptionally regulate gene expression. Their canonical function depends on a “seed” sequence at the miRNA 5′ end that pairs with conserved sites in the 3′ untranslated regions of target messenger RNAs to suppress gene expression. Although seed–mediated targeting is well characterized, the role of the miRNA 3′ end remains poorly understood and is challenging to study. Here, we identify a noncanonical mechanism by which miR–106a, a member of the miR–17 family, competes with let–7a for binding to let–7 target sites despite their distinct seed sequences. This binding bypasses miR–106a seed pairing and instead relies on extensive complementarity at its 3′ end, which shares sequence identity with the let–7a seed. Such binding of miR–106a does not itself silence these targets but shields them from let–7–mediated suppression, resulting in de-repression of let–7 targets. By contrast, miR–106b, which differs from miR–106a and the other miR–17 family members at its 3′ end, lacks this de-repressive activity. These findings show that variation in miRNA 3′ sequences can generate divergent functions within a miRNA family and underscore the need to account for 3′–end contributions when interpreting miRNA–target networks and considering the development of miRNA–based therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, 8093, Switzerland.
- Bioinformatics Competence Centre, University of Lausanne, Lausanne, 1015, Switzerland.
- Tumor Biology and Experimental Therapeutics, Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, 6500, Switzerland.
- Biozentrum, University of Basel, Spitalstrasse 41, Basel 4056, Switzerland.
- Max Planck Institute of Molecular Physiology, Chemical Genomics Centre, Dortmund 44227, Germany.
- Department for Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, United States.
ORCID-Profile: Anneke Brümmer, Elisa Federici, Iris Mestres-Pascual, Jochen Imig, Mihaela Zavolan, Ian J MacRae, Carlo V Catapano, Jonathan Hall
Förderung
- NIGMS NIH HHS
- Krebsliga Schweiz
- Foundation Nelia and Amadeo Barletta
- ETH Zurich
Zitieren
APA
Laski, A., Brümmer, A., Lucic, M., Federici, E., Mestres-Pascual, I., Imig, J., Kanitz, A., Zavolan, M., Gebert, L. F. R., MacRae, I. J., Catapano, C. V., & Hall, J. (2026). Seedless 3′ pairing enables miR-17 family miRNAs to seize let-7 target sites. Nucleic Acids Research, 54(15). https://doi.org/10.1093/nar/gkag767
Vancouver
Laski A, Brümmer A, Lucic M, Federici E, Mestres-Pascual I, Imig J, et al. Seedless 3′ pairing enables miR-17 family miRNAs to seize let-7 target sites. Nucleic Acids Research. 2026;54(15). doi:10.1093/nar/gkag767
BibTeX
@article{Laski2026,
author = {Laski, Artur and Brümmer, Anneke and Lucic, Matije and Federici, Elisa and Mestres-Pascual, Iris and Imig, Jochen and Kanitz, Alexander and Zavolan, Mihaela and Gebert, Luca F R and MacRae, Ian J and Catapano, Carlo V and Hall, Jonathan},
title = {Seedless 3′ pairing enables miR-17 family miRNAs to seize let-7 target sites},
journal = {Nucleic Acids Research},
year = {2026},
volume = {54},
number = {15},
doi = {10.1093/nar/gkag767}
}
EUVIMED